Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.

ABSTRACT:

Background

Little is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib.

Methods

Risk factors for GIST recurrence were identified, and 2 risk stratification scores were developed using the database of the Scandinavian Sarcoma Group (SSG) XVIII trial, where 358 patients with high-risk GIST with no overt metastases were randomly assigned to adjuvant imatinib 400 mg/day either for 12 or 36 months after surgery. The findings were validated in the imatinib arm of the American College of Surgeons Oncology Group Z9001 trial, where 359 patients with GIST were randomized to receive imatinib and 354 were to receive placebo for 12 months.

Results

Five factors (high tumor mitotic count, nongastric l

SUBMITTER: Joensuu H 

PROVIDER: S-EPMC4209960 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature